Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
4.700
-0.170 (-3.49%)
At close: Oct 24, 2025, 4:00 PM EDT
4.640
-0.060 (-1.28%)
After-hours: Oct 24, 2025, 7:43 PM EDT
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
32.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 41.18M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NERV News
- 3 days ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 2 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 5 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 8 months ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - US FDA declines to approve Minerva Neurosciences' schizophrenia drug - Reuters
- 1 year ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - GlobeNewsWire